Ultrashort Echo Time (UTE) MRI for Applicator Reconstruction in Gynaecologic Cancer Brachytherapy (UTE)
The goal of this clinical study is to learn whether an ultrashort echo time (UTE) MRI scan can show the position of brachytherapy applicators and needles more accurately than standard MRI scans in adults with gynaecologic cancer (cervical, endometrial, or vaginal cancer) who are receiving MRI-guided internal radiotherapy (brachytherapy).
The main questions it aims to answer are:
- Does UTE MRI locate the applicator and needle tips more accurately than standard T2-weighted (T2W) and proton-density-weighted (PDW) MRI, when compared with CT?
- Does UTE MRI show a clearer contrast between the applicator and the surrounding tissue?
Researchers will compare applicator positions reconstructed from UTE, T2W, and PDW MRI with CT taken on the same day as the reference standard. They will also check whether differences in applicator reconstruction change the planned radiation dose, and whether image features (radiomics) from UTE MRI before treatment and before brachytherapy help predict cancer recurrence.
Participants will:
- Receive their usual standard brachytherapy treatment, which is not changed by this study
- Have one additional MRI sequence (UTE, about 8 minutes) added to their standard MRI and CT scans at each brachytherapy planning session, with the applicator in place
- Have an additional UTE sequence added to their routine MRI before treatment and before brachytherapy
- Be followed during routine clinical visits for disease outcomes
調査の概要
詳細な説明
Background MRI-guided adaptive brachytherapy is the standard of care for locally advanced gynaecologic cancer. T2-weighted MRI is the reference sequence for target delineation, but applicator and interstitial needle reconstruction on T2W MRI is limited by low contrast between the uterus and titanium applicators and by susceptibility artefacts, with reported geometric distortion of up to about 7 mm. Proton-density-weighted MRI (TE about 5.5 ms) improves tandem visualisation but remains limited for interstitial needles and residual blooming artefact. Ultrashort echo time (UTE) MRI (TE below 1 ms) captures signal from very short-T2 structures and is expected to reduce susceptibility artefact around metallic and plastic applicators. No prospective study has compared UTE with PDW and T2W MRI for intracavitary/interstitial applicator reconstruction in gynaecologic brachytherapy.
Hypothesis UTE MRI will localise the applicator tip more accurately than PDW and T2W MRI, with a mean tip-localisation error of no more than 1.2 mm relative to same-day CT, and will provide a higher uterus-to-applicator contrast-to-noise ratio (CNR), with about 8 minutes of additional scan time.
Study design Single-centre, prospective, single-group study at the Division of Radiation Oncology, Faculty of Medicine Siriraj Hospital, Mahidol University. Standard treatment is not altered.
Phase 1 - Phantom validation An MR- and CT-compatible phantom holding tandem-ring, tandem-ovoid, vaginal cylinder, intracavitary/interstitial applicators and interstitial needles in multiple orientations will be imaged with CT and MRI (T1W, T2W, UTE) without moving the applicator. Image quality (SNR, CNR, apparent applicator diameter, tip/channel visibility, geometric distortion, susceptibility artefact) will be assessed. Source dwell positions will be verified by autoradiography using an Ir-192 source. Dosimetric impact will be assessed with AAPM TG-43 calculations on simulated targets and organs at risk.
Phase 2 - Clinical validation After applicator insertion, at each brachytherapy planning session participants will undergo standard CT and MRI (T2W, PDW) with an additional 3D UTE sequence (1.5 mm isotropic, TE below 0.1 ms) on a Philips 1.5T Ingenia Ambition X system, with the applicator in situ and minimal time between scans. Three experienced medical physicists will independently reconstruct applicators on each image set, blinded and in randomised order. Applicator-based rigid registration between CT and MRI with a registration quality score will be used to separate reconstruction error from applicator displacement; only registrations meeting predefined acceptance criteria will be analysed. Comparison plans (CT reference, T2W, UTE) will use identical contours, dwell positions, and dwell times so that dose differences reflect reconstruction alone.
Phase 3 - Radiomics An additional UTE sequence will be acquired with routine T2W and DWI at pre-treatment and pre-brachytherapy time points. Radiomic features will be extracted from tumour ROIs (MIM software) and evaluated for prognostic value for locoregional and distant recurrence, in addition to existing T2W- and DWI-based models, using Kaplan-Meier and Cox proportional hazards analyses.
Sample size and analysis Target enrolment is 50 adult patients (about 150 imaging sessions). Assuming tip error of 1.2 +/- 1.0 mm for UTE versus 1.8 +/- 1.2 mm for PDW, a paired t-test with two-sided alpha 0.05 and 80% power (d = 0.46) was used. Agreement with CT will be assessed by Bland-Altman analysis; sequences will be compared with repeated-measures ANOVA or linear mixed-effects models; inter- and intra-observer agreement by ICC; and dosimetric parameters (CTV-HR D90/D98, OAR D2cc and others) with correction for multiple comparisons.
Support Philips (Thailand) Ltd. provides research equipment support without funding. The company has no role in study design, participant selection, data collection, analysis, interpretation, writing, or the decision to publish.
研究の種類
入学 (推定)
段階
- 適用できない
連絡先と場所
研究連絡先
- 名前:Tissana Prasartseree, M.D.
- 電話番号:66625246101
- メール:tissana.p@gmail.com
研究連絡先のバックアップ
- 名前:Pittaya Dankulchai, M.D.
- 電話番号:66966233606
- メール:pittaya.dan@mahidol.ac.th
研究場所
-
-
Bangkok
-
Bangkok、Bangkok、タイ、10700
- Faculty of Medicine Siriraj Hospital, Mahidol University
-
コンタクト:
- Tissana Prasartseree, M.D.
- 電話番号:66625246101
- メール:tissana.p@gmail.com
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Gynaecologic malignancy (cervix/endometrium/vagina) requiring BT with intracavitary or hybrid IC/IS applicator
- Locally advanced cervical, endometrial, or vaginal cancer undergoing MRI-guided BT
- Age ≥ 18 years
- ECOG 0-2
- Written informed consent
Exclusion Criteria:
- MRI contraindication (incompatible implant, severe claustrophobia)
- non-MRI-compatible applicator required
- inability to tolerate ~8 mins additional scan time
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:診断
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:UTE MRI
Gynaecologic malignancy (cervix/endometrium/vagina) requiring BT with intracavitary or hybrid IC/IS applicator. At every planning/fraction session: T2W, PDW, 3D UTE (1.5 mm isotropic) and same day CT (reference), all with applicator in situ on a Philips 1.5T system. An additional UTE sequence will be acquired alongside the standard T2W and DWI sequences at pre-treatment and pre-brachytherapy time points. |
Ultrashort Echo Time sequence (EFO 033), TE < 0.1 ms, investigational Philips sequence, on Philips 1.5T MR Systems Ingenia Ambition X release 5.7. 3D UTE (1.5 mm isotropic) acquired at every planning/fraction session with applicator in situ, in addition to T2W and PDW (~8 mins additional scan time).
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Applicator/needle tip-localisation error
時間枠:Periprocedural: after applicator insertion, at every planning/fraction session (~150 imaging sessions)
|
Applicator/needle tip-localisation error of UTE among the T2W, PDW MRI sequences, using same day CT as reference (geometric gold standard). Reported in millimetres. |
Periprocedural: after applicator insertion, at every planning/fraction session (~150 imaging sessions)
|
|
Contrast-to-noise ratio (CNR)
時間枠:Periprocedural: after applicator insertion, at every planning/fraction session (~150 imaging sessions)
|
Contrast-to-noise ratio (CNR) between uterus and applicator of UTE among the T2W and PDW MRI sequences. |
Periprocedural: after applicator insertion, at every planning/fraction session (~150 imaging sessions)
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Percentage dose difference of brachytherapy plan from UTE among the T2W, PDW MRI sequences and CT
時間枠:Periprocedural: after applicator insertion, at every planning/fraction session (~150 imaging sessions)
|
Dosimetric agreement of brachytherapy plan from UTE among the T2W, PDW MRI sequences and CT, including CTV-HR D90, CTV-HR D98, CTV-HR V100, CTV-IR D90, CTV-IR D98, and Bladder, Rectum, Sigmoid Colon and Small Bowel D0.1cc, D1cc and D2cc. |
Periprocedural: after applicator insertion, at every planning/fraction session (~150 imaging sessions)
|
|
Radiomics prognostic value for locoregional and distant recurrence
時間枠:Pre-treatment and pre-brachytherapy timepoints, followed up to 3 years
|
Radiomics with UTE at pre-treatment and pre-brachytherapy timepoints for locoregional and distant recurrent prognostic value in addition to the existing T2W- and DWI-based model (Kaplan-Meier survival analysis and Cox regression analysis). Reported as Hazard Ratio (HR) with 95% CI. |
Pre-treatment and pre-brachytherapy timepoints, followed up to 3 years
|
協力者と研究者
スポンサー
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
追加の関連 MeSH 用語
その他の研究ID番号
- Si 784/2569(IRB1)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。